10-K: Charlotte's Web Holdings Reports FY24 Results, Navigates Regulatory Uncertainty

Charlotte's Web Holdings details its FY24 performance, highlighting revenue decline and strategic shifts amid a complex regulatory landscape.

Summary

• Charlotte's Web Holdings, Inc., a leader in hemp-derived CBD wellness products, released its Form 10-K for the fiscal year ended December 31, 2024.
• The company reported a decrease in revenue to $49.7 million, a 21.4% decline compared to the previous year.
• This decrease was attributed to lower average order values, inflationary pressures, and retailer challenges in the CBD category.
• Cost of goods sold increased slightly, primarily due to a $4.2 million increase in inventory provisions.
• Selling, general, and administrative expenses decreased by 29.6% due to cost-cutting measures.
• The company reported a net loss of $29.8 million for the year.
• Charlotte's Web is adapting its product portfolio, including expanding into hemp-free functional mushroom gummies and CBN gummies.
• The company is navigating a complex and evolving regulatory environment for hemp-derived products, both in the U.S. and internationally.
• The company is also involved in a collaboration with DeFloria, Inc. to develop a botanical drug for autism spectrum disorder.
• As of December 31, 2024, the company had cash and cash equivalents of $22.6 million.

Sentiment

Score: 5

Explanation: The document presents a mixed sentiment. While the company is taking steps to innovate and cut costs, the financial results show a decline in revenue and a net loss. The regulatory uncertainty adds to the cautious outlook.

Positives

• The company is expanding its product portfolio with new functional mushroom and CBN gummy lines.
• Selling, general, and administrative expenses decreased due to cost-cutting measures.
• Collaboration with DeFloria, Inc. is progressing, with FDA allowing Phase 2 clinical trials for a botanical drug.
• The company extended its MLB Promotional Rights Agreement, providing continued brand exposure.

Negatives

• FY24 revenue decreased by 21.4% compared to the previous year.
• Cost of goods sold increased slightly due to inventory provisions.
• The company reported a net loss of $29.8 million for the year.
• The company faces ongoing regulatory uncertainty surrounding hemp-derived products.

Risks

• The regulatory environment surrounding hemp is uncertain and subject to change.
• The company faces intense competition in the CBD wellness products space.
• Changing consumer preferences could impact the company's ability to attract and retain customers.
• The company depends on key personnel and its ability to attract and retain employees.
• The company may have difficulty accessing public and private capital and banking services.
• The company's internal controls over financial reporting may not be effective.

Future Outlook

The company is working to capitalize on the rapidly emerging botanical-based wellness products industry by driving customer acquisition and retention, as well as accelerating national and international retail expansion. In addition, the Company may consider expanding its product line beyond hemp-based products and functional mushrooms should the science and the Companys strategic vision support such expansion.

Management Comments

• Charlottes Webs mission is to unearth the science of nature to revolutionize wellness.
• The above statements capture the essence of the Companys business strategy and the pioneering vision of its founders.
• The Company strives to realize significant growth by expanding further into the health and wellness sector, while capitalizing on the Companys unique differentiators to create sustainable value.

Industry Context

The company operates in the competitive and evolving CBD and hemp extracts industries, facing competition from both existing and emerging companies. The company is also navigating a complex and evolving regulatory environment for hemp-derived products, both in the U.S. and internationally.

Comparison to Industry Standards

• The Company's principal competitors in the CBD wellness products space include companies such as , Medterra, SUNMED, Global Widget, CBD American Shaman, CBDfx, Wyld and PlusCBD .
• The Company's products meet regulatory guidelines for contaminants and are tested by independent third-party laboratories.
• The Company employs cGMP at each stage of its production.

Management Changes

Related Party Transactions

• The Company has a secured promissory note with one of the Stanley Brothers, which has been fully reserved for.
• The Company entered into a Brand License and Option Agreement with JMS Brands LLC, an entity owned by one of the Stanley Brothers, which has expired.
• The Company jointly formed DeFloria, Inc. with AJNA BioSciences PBC, which is partially owned and was co-founded by certain of the Stanley Brothers.
• The Company entered into a master services agreement with DeFloria, Inc. pursuant to which the Company will be compensated for the provision of certain services to DeFloria.
• The Company entered into a consulting agreement with Jared Stanley, former executive of the Company, and current member of the Board of Directors.

Stakeholder Impact

• The company's performance and strategic decisions impact shareholders, employees, customers, suppliers, and the communities in which it operates.
• The company's commitment to being a benefit company and a Certified B Corp reflects its consideration of the interests of all stakeholders.

Next Steps

• The company expects to begin manufacturing gummy and topical products at the LOFT in 2025.
• The company will continue to engage with the FDA and lawmakers with the objective of securing a favorable ruling and/or facilitating the enactment of definitive legislation establishing an appropriate regulatory environment to protect consumers and to establish guidance for manufacturers and marketers of CBD-containing dietary supplements.

Key Dates